Monoclonal CD38 antibodies can be used to expand the response to other immunotherapeutic approaches to treat MM, such as chimeric antigen receptor T cell (CAR-T) and CD38/CD3 bispecific T-cell engager (BiTE) therapies. Here, CD38 is linked to Miyoshi myopathy.